Neuropsychobiology

Original Paper

Plasma BDNF Level in Major Depression: Biomarker of the Val66Met BDNF Polymorphism and of the Clinical Course in Met Carrier Patients

Colle R.a · Trabado S.b · David D.J.c · Brailly-Tabard S.b · Hardy P.a · Falissard B.d · Fève B.e, f · Becquemont L.g, h · Verstuyft C.g,i,j · Corruble E.a

Author affiliations

aINSERM UMR 1178, Université Paris Sud, Service de Psychiatrie, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, and bINSERM 1185, Faculté de Médicine Paris Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Hôpital de Bicêtre, Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, Le Kremlin Bicêtre, cINSERM UMR 1178, Université Paris Sud, Faculté de Pharmacie, Châtenay-Malabry, dINSERM UMR 1178, CESP, Département de Biostatistiques, Université Paris Sud, Hôpital Paul Brousse, Assistance Publique Hôpitaux de Paris, Villejuif, eService d'endocrinologie, Hôpital Saint-Antoine, Assistance Publique Hôpitaux de Paris, and fSorbonne Universities, Université Paris 6, INSERM UMR S_938, Centre de Recherche Saint-Antoine, Paris, gIINSERM UMR 1178, Université Paris Sud, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, hCentre de Recherche Clinique (CRC), Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, iService de Génétique Moléculaire, Pharmacogénétique et Hormonologie, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, and jCentre de Ressources Biologique de Paris-Sud, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Le Kremlin Bicêtre, France

Keywords: Brain-derived neurotrophic factorVal66Met polymorphismGeneticsPlasma brain-derived neurotrophic factorMajor depressive disorderMajor depressive episode

Related Articles for ""
Neuropsychobiology 2017;75:39-45
https://doi.org/10.1159/000478862

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: September 01, 2016
Accepted: June 19, 2017
Published online: August 23, 2017
Issue release date: November 2017

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 1

ISSN: 0302-282X (Print)
eISSN: 1423-0224 (Online)

For additional information: https://www.karger.com/NPS

Abstract

Aims: Despite the involvement of the brain-derived neurotrophic factor (BDNF) in the physiopathology of major depressive disorder (MDD), the coherence between the components of the BDNF pathway and their link with the clinical features of MDD are insufficiently studied. We aimed to assess in Caucasian depressed patients the impact of the BDNF Val66Met polymorphism on plasma BDNF levels taking into account the clinical characteristics of MDD. Methods: A total of 328 Caucasian adult MDD patients with a current major depressive episode (MDE) were assessed for the BDNF Val66Met polymorphism, plasma BDNF levels and clinical characteristics of the MDD. Results: Plasma BDNF levels were linearly associated with the BDNF Val66Met genotypes (ValVal: 1,525.9 ± 1,183.3 pg/mL vs. ValMet: 1,248.7 ± 1,081.8 vs. MetMet: 1,004.9 ± 952.8; p = 0.04), Met carriers having lower BDNF levels than ValVal ones. Significant interactions between the Val66Met polymorphism and 3 clinical characteristics - age at onset (p = 0.03), MDD duration (p = 0.04), and number of previous MDE (p = 0.04) - were evidenced for plasma BDNF levels. Indeed, in Met carriers, but not in ValVal ones, plasma BDNF levels were negatively correlated with age at onset and positively correlated with MDD duration and number of previous MDE. Conclusion: Our results show a measurable, coherent, and functional BDNF pathway based on the BDNF Val66Met polymorphism and plasma BDNF levels in patients with a current MDE. This pathway is related to the clinical course of major depression, plasma BDNF levels being associated with the long-term history of MDD in Met carriers. Further studies assessing central BDNF are needed to understand the underlying mechanisms of this association.

© 2017 S. Karger AG, Basel



Related Articles:

References

  1. Castren E, Rantamaki T: The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev Neurobiol 2010;70:289-297.
    External Resources
  2. Notaras M, Hill R, van den Buuse M: The BDNF gene Val66Met polymorphism as a modifier of psychiatric disorder susceptibility: progress and controversy. Mol Psychiatry 2015;20:916-930.
    External Resources
  3. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR: The BDNF Val66Met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003;112:257-269.
    External Resources
  4. Pattwell SS, Bath KG, Perez-Castro R, Lee FS, Chao MV, Ninan I: The BDNF Val66Met polymorphism impairs synaptic transmission and plasticity in the infralimbic medial prefrontal cortex. J Neurosci 2012;32:2410-2421.
    External Resources
  5. Kang RH, Chang HS, Wong ML, Choi MJ, Park JY, Lee HY, Jung IK, Joe SH, Kim L, Kim SH, Kim YK, Han CS, Ham BJ, Lee HJ, Ko YH, Lee MS, Lee MS: Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. J Psychopharmacol 2010;24:1755-1763.
    External Resources
  6. You J, Yuan Y, Shi Y, Zhang Z, Zhang X, Li H: Lack of association between BDNF Val66Met gene polymorphism and late-onset depression in a Chinese Han population. Acta Neuropsychiatr 2009;21:186-190.
    External Resources
  7. Polyakova M, Stuke K, Schuemberg K, Mueller K, Schoenknecht P, Schroeter ML: BDNF as a biomarker for successful treatment of mood disorders: a systematic and quantitative meta-analysis. J Affect Disord 2015;174:432-440.
    External Resources
  8. Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, Knudsen GM, Aznar S: Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol 2011;14:347-353.
    External Resources
  9. Dell'Osso L, Del Debbio A, Veltri A, Bianchi C, Roncaglia I, Carlini M, Massimetti G, Catena Dell'Osso M, Vizzaccaro C, Marazziti D, Piccinni A: Associations between brain-derived neurotrophic factor plasma levels and severity of the illness, recurrence and symptoms in depressed patients. Neuropsychobiology 2010;62:207-212.
    External Resources
  10. Verhagen M, van der Meij A, van Deurzen PA, Janzing JG, Arias-Vasquez A, Buitelaar JK, Franke B: Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol Psychiatry 2010;15:260-271.
    External Resources
  11. Colle R, Deflesselle E, Martin S, David DJ, Hardy P, Taranu A, Falissard B, Verstuyft C, Corruble E: BDNF/TRKB/P75NTR polymorphisms and their consequences on antidepressant efficacy in depressed patients. Pharmacogenomics 2015;16:997-1013.
    External Resources
  12. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33; quiz 34-57.
    External Resources
  13. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
    External Resources
  14. Coulbault L, Beaussier M, Verstuyft C, Weickmans H, Dubert L, Tregouet D, Descot C, Parc Y, Lienhart A, Jaillon P, Becquemont L: Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther 2006; 79:316-324.
    External Resources
  15. Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P, Virchow JC: The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 2005;26:115-123.
    External Resources
  16. Terracciano A, Martin B, Ansari D, Tanaka T, Ferrucci L, Maudsley S, Mattson MP, Costa PT Jr: Plasma BDNF concentration, Val66Met genetic variant and depression-related personality traits. Genes Brain Behav 2010;9:512-518.
    External Resources
  17. Driscoll I, Martin B, An Y, Maudsley S, Ferrucci L, Mattson MP, Resnick SM: Plasma BDNF is associated with age-related white matter atrophy but not with cognitive function in older, non-demented adults. PLoS One 2012;7:e35217.
    External Resources
  18. Begliuomini S, Casarosa E, Pluchino N, Lenzi E, Centofanti M, Freschi L, Pieri M, Genazzani AD, Luisi S, Genazzani AR: Influence of endogenous and exogenous sex hormones on plasma brain-derived neurotrophic factor. Hum Reprod 2007;22:995-1002.
    External Resources
  19. Colle R, Trabado S, Rotenberg S, Brailly-Tabard S, Benyamina A, Aubin HJ, Hardy P, Falissard B, Becquemont L, Verstuyft C, Fève B, Corruble E: Tobacco use is associated with increased plasma BDNF levels in depressed patients. Psychiatry Res 2016;246:370-372.
    External Resources
  20. Bender R, Lange S: Adjusting for multiple testing - when and how? J Clin Epidemiol 2001;54:343-349.
    External Resources
  21. Li H, Liu L, Tang Y, Ji N, Yang L, Qian Q, Wang Y: Sex-specific association of brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and plasma BDNF with attention-deficit/hyperactivity disorder in a drug-naive Han Chinese sample. Psychiatry Res 2014;217:191-197.
    External Resources
  22. Chen SL, Lee SY, Chang YH, Chen SH, Chu CH, Wang TY, Chen PS, Lee IH, Yang YK, Hong JS, Lu RB: The BDNF Val66Met polymorphism and plasma brain-derived neurotrophic factor levels in Han Chinese patients with bipolar disorder and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2014;51:99-104.
    External Resources
  23. Chen SL, Lee SY, Chang YH, Wang TY, Chen SH, Chu CH, Chen PS, Yang YK, Hong JS, Lu RB: The BDNF Val66Met polymorphism and plasma brain-derived neurotrophic factor levels in Han Chinese heroin-dependent patients. Sci Rep 2015;5:8148.
    External Resources
  24. Wang Y, Zhang H, Li Y, Wang Z, Fan Q, Yu S, Lin Z, Xiao Z: BDNF Val66Met polymorphism and plasma levels in Chinese Han population with obsessive-compulsive disorder and generalized anxiety disorder. J Affect Disord 2015;186:7-12.
    External Resources
  25. Wang LJ, Chen CK, Hsu HJ, Wu IW, Sun CY, Lee CC: Depression, 5HTTLPR and BDNF Val66Met polymorphisms, and plasma BDNF levels in hemodialysis patients with chronic renal failure. Neuropsychiatr Dis Treat 2014;10:1235-1241.
    External Resources
  26. Zakharyan R, Boyajyan A: Brain-derived neurotrophic factor blood levels are decreased in schizophrenia patients and associate with rs6265 genotypes. Clin Biochem 2014;47:1052-1055.
    External Resources
  27. Luykx JJ, Boks MP, Breetvelt EJ, Aukes MF, Strengman E, da Pozzo E, Dell'Osso L, Marazziti D, van Leeuwen A, Vreeker A, Abramovic L, Martini C, Numans ME, Kahn RS, Ophoff RA: BDNF Val66Met homozygosity does not influence plasma BDNF levels in healthy human subjects. Prog Neuropsychopharmacol Biol Psychiatry 2013;43:185-187.
    External Resources
  28. Mercader JM, Fernandez-Aranda F, Gratacos M, Ribases M, Badia A, Villarejo C, Solano R, Gonzalez JR, Vallejo J, Estivill X: Blood levels of brain-derived neurotrophic factor correlate with several psychopathological symptoms in anorexia nervosa patients. Neuropsychobiology 2007;56:185-190.
    External Resources
  29. Iga J, Ueno S, Yamauchi K, Numata S, Tayoshi-Shibuya S, Kinouchi S, Nakataki M, Song H, Hokoishi K, Tanabe H, Sano A, Ohmori T: The Val66Met polymorphism of the brain-derived neurotrophic factor gene is associated with psychotic feature and suicidal behavior in Japanese major depressive patients. Am J Med Genet B Neuropsychiatr Genet 2007;144B:1003-1006.
    External Resources
  30. Hong CJ, Huo SJ, Yen FC, Tung CL, Pan GM, Tsai SJ: Association study of a brain-derived neurotrophic-factor genetic polymorphism and mood disorders, age of onset and suicidal behavior. Neuropsychobiology 2003;48:186-189.
    External Resources
  31. Kreinin A, Lisson S, Nesher E, Schneider J, Bergman J, Farhat K, Farah J, Lejbkowicz F, Yadid G, Raskin L, Koman I, Pinhasov A: Blood BDNF level is gender specific in severe depression. PLoS One 2015;10:e0127643.
    External Resources
  32. Gonul AS, Kitis O, Eker MC, Eker OD, Ozan E, Coburn K: Association of the brain-derived neurotrophic factor Val66Met polymorphism with hippocampus volumes in drug-free depressed patients. World J Biol Psychiatry 2011;12:110-118.
    External Resources
  33. Domschke K, Lawford B, Laje G, Berger K, Young R, Morris P, Deckert J, Arolt V, McMahon FJ, Baune BT: Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int J Neuropsychopharmacol 2010;13:93-101.
    External Resources
  34. Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C, Fischer CP, Lindegaard B, Petersen AM, Taudorf S, Secher NH, Pilegaard H, Bruunsgaard H, Pedersen BK: Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 2007;50:431-438.
    External Resources
  35. Chimienti G, Mezzapesa A, Rotelli MT, Lupo L, Pepe G: Plasma concentrations but not serum concentrations of brain-derived neurotrophic factor are related to pro-inflammatory cytokines in patients undergoing major abdominal surgery. Clin Biochem 2012;45:631-636.
    External Resources
  36. Lotrich FE, Albusaysi S, Ferrell RE: Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-alpha treatment. Neuropsychopharmacology 2013;38:985-995.
    External Resources
  37. Pei Y, Smith AK, Wang Y, Pan Y, Yang J, Chen Q, Pan W, Bao F, Zhao L, Tie C, Wang Y, Wang J, Zhen W, Zhou J, Ma X: The brain-derived neurotrophic-factor (BDNF) Val66Met polymorphism is associated with geriatric depression: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2012;159B:560-566.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: September 01, 2016
Accepted: June 19, 2017
Published online: August 23, 2017
Issue release date: November 2017

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 1

ISSN: 0302-282X (Print)
eISSN: 1423-0224 (Online)

For additional information: https://www.karger.com/NPS

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2017, Vol.75, No. 1

November 2017

Article

Recommend This
TOP